ALX hopes to gain insights by tracking EGFR expression in a new trial of ALX2004 and to identify best responders using CD47 expression in a trial of evorpacept.

This clinical study update could impact AstraZeneca’s stock performance positively by showcasing its commitment to innovative cancer treatments. Investors may view this as a strategic move to ...

Explore our latest breakthroughs in Esophageal Cancer Research. Learn more about our innovative pipeline today! @ Esophageal ...

Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a ...

Esophageal carcinoma (EC) is a tumor type of the digestive tract that accounts for about 300,000 deaths worldwide annually, with high aggressiveness and poor prognosis. Chinese researchers have ...